Patents by Inventor Paul Barraclough
Paul Barraclough has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130005732Abstract: Compounds of formula (I): especially where R1 is an optionally substituted alkyl, aralkyl or heterocyclyl-alkyl group, are shown to have activity as sodium channel blockers or as antifolates. Some novel compounds where R1 is an aralkyl or heterocyclyl-alkyl are disclosed.Type: ApplicationFiled: September 13, 2012Publication date: January 3, 2013Applicant: University of GreenwichInventors: Michael LEACH, Laurence HARBIGE, Dieter RIDDALL, Paul BARRACLOUGH
-
Patent number: 8268823Abstract: Compounds of formula (I) especially where R1 is an optionally substituted alkyl, aralkyl or heterocyclyl-alkyl group, are shown to have activity as sodium channel blockers or as antifolates. Some novel compounds where R1 is an aralkyl or heterocyclyl-alkyl are disclosed.Type: GrantFiled: July 13, 2007Date of Patent: September 18, 2012Assignee: University of GreenwichInventors: Michael Leach, Laurence Harbige, Dieter Riddall, Paul Barraclough
-
Publication number: 20120142775Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of ?-linolenic acid, dihomo-?-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-?1 levels in the patient to therapeutic levels.Type: ApplicationFiled: February 1, 2012Publication date: June 7, 2012Applicant: BTG International LimitedInventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief, Paul Barraclough
-
Patent number: 8114903Abstract: A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R1 and R2 together form a group —(CH2)n—CR4R5—(CH2)m— wherein n and m are independently selected integers 0, 1 or 2 and R4 and R5 are independently selected from H, C1-18 alkyl, C1-18alkoxy, C1-18n hydroxyalkyl, C2-18 alkenyl and C6-18aryl or aralykyl and R3 is the a fatty acyl group of an essential polyunsaturated fatty acid.Type: GrantFiled: July 2, 2010Date of Patent: February 14, 2012Assignee: BTG International LimitedInventors: Laurence S. Harbige, Michael J. Leach, Paul Barraclough, Anthony P Dolan
-
Patent number: 7964641Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of ?-linolenic acid, dihomo-?-linolenic acid and arachidonic acid characterized in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-?1 levels in the patient to therapeutic levels.Type: GrantFiled: August 13, 2004Date of Patent: June 21, 2011Assignee: BTG International LimitedInventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief, Paul Barraclough
-
Publication number: 20100297196Abstract: A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R1 and R2 together form a group —(CH2)n—CR4R5—(CH2)m— wherein n and m are independently selected integers 0, 1 or 2 and R4 and R5 are independently selected from H, C1-18 alkyl, C1-18alkoxy, C1-18hydroxyalkyl, C2-18 alkenyl and C6-18aryl or aralykyl and R3 is the a fatty acyl group of an essential polyunsaturated fatty acid.Type: ApplicationFiled: July 2, 2010Publication date: November 25, 2010Applicant: BTG International LimitedInventors: Laurence S. Harbige, Michael J. Leach, Paul Barraclough, Anthony P. Dolan
-
Publication number: 20100113810Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of ?-linolenic acid, dihomo-?-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-?1 levels in the patient to therapeutic levels.Type: ApplicationFiled: December 31, 2009Publication date: May 6, 2010Applicant: BTG International LimitedInventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief, Paul Barraclough
-
Publication number: 20100113595Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of ?-linolenic acid, dihomo-?-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-?1 levels in the patient to therapeutic levels.Type: ApplicationFiled: December 31, 2009Publication date: May 6, 2010Applicant: BTG International LimitedInventors: Lawrence S. Harbige, Michael J. Leach, Mohammed Sharief, Paul Barraclough
-
Publication number: 20100087411Abstract: The invention discloses substituted sapogenins and their use in the treatment of cognitive disfunction and similar conditions.Type: ApplicationFiled: August 11, 2009Publication date: April 8, 2010Applicant: Phytopharm PLCInventors: Paul Barraclough, Jim Hanson, Phil Gunning, Daryl Rees, Zongqin Xia, Yaer Hu
-
Publication number: 20090291954Abstract: Compounds of formula (I) especially where R1 is an optionally substituted alkyl, aralkyl or heterocyclyl-alkyl group, are shown to have activity as sodium channel blockers or as antifolates. Some novel compounds where R1 is an aralkyl or hetero-cyclyl-alkyl are disclosed.Type: ApplicationFiled: July 13, 2007Publication date: November 26, 2009Applicant: University of GreenwichInventors: Michael Leach, Laurence Harbige, Dieter Riddall, Paul Barraclough
-
Patent number: 7589123Abstract: Compounds of general formula I: wherein: R1 and R2 are, independently of each other, selected from hydrogen, optionally substituted C1-10alkyl, optionally substituted —CO—(C1-10alkyl), optionally substituted C3-10cycloalkyl, optionally substituted —CO—(C3-10cycloalkyl), optionally substituted C2-10alkenyl, optionally substituted —CO—(C2-10alkenyl), optionally substituted aryl, and optionally substituted —CO-aryl, or R1 and R2 together represent an optionally substituted saturated or unsaturated C1-10alkylidene group, or an optionally substituted saturated or unsaturated C3-10cycloalkylidene group, or R1 and R2 together with the carbon atom to which they are attached represent an optionally substituted saturated or unsaturated organic ring containing 3, 4, 5, 6, 7 or 8 ring carbon atoms and optionally 1, 2 or 3 ring heteroatoms selected from O, N and S; R3, which may be the same as, or different from, either of R1 and R2, is selected from optionally substituted C1-10alkyl, optionally substituted C3-10cyclType: GrantFiled: July 5, 2007Date of Patent: September 15, 2009Assignee: Phytopharm PLCInventors: Daryl David Rees, Phillip James Gunning, Antonia Orsi, Patrick A. Howson, Paul Barraclough, Noelle Callizot
-
Publication number: 20090137660Abstract: A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R1 and R2 together form a group —(CH2)n—CR4R5—(CH2)m— wherein n and m are independently selected integers 0, 1 or 2 and R4 and R5 are independently selected from H, C1-18 alkyl, C1-18 alkoxy, C1-18n hydroxyalkyl, C2-18 alkenyl and C6-18 aryl or aralyalkyl and R3 is the fatty acyl group of an essential polyunsaturated fatty acid.Type: ApplicationFiled: March 2, 2006Publication date: May 28, 2009Inventors: Laurence S. Harbige, Michael J. Leach, Paul Barraclough, Anthony P. Dolan
-
Patent number: 7507720Abstract: The invention discloses the use of sapogenin derivatives in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical compositions are also disclosed.Type: GrantFiled: August 11, 2006Date of Patent: March 24, 2009Assignee: Phytopharm PLCInventors: Paul Barraclough, Jim Hanson, Phil Gunning, Daryl Rees, Zongqin Xia, Yaer Hu
-
Publication number: 20090036410Abstract: A method of treating a patient in need of therapy for a disease in which cyokines have become dysregulated, or are otherwise capable of modulation to provide therapeutic benefit, is provided comprising administering to that patient a therapeutically effective dose of a phospholipid comprising a phosphatidyl group esterifed with one or more fatty acyl groups, characterised in that the phospholipid has at least one fatty acyl group at the sn-1 and/or sn-2 position of the phosphatidyl group, the fatty acyl group being selected from the group consisting of ?-linolenoyl, dihomo-?-linolenoyl acid and arachidonoyl.Type: ApplicationFiled: November 25, 2005Publication date: February 5, 2009Applicant: BTG INTERNATIONAL LIMITEDInventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief, Paul Barraclough
-
Publication number: 20090023807Abstract: A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a monoglyceride or metabolic precursor thereof of general formula (I), wherein R1 is the fatty acyl group of an essential polyunsaturated fatty acid selected from ?-linolenoyl, ?-dihomolinolenoyl and arachidonoyl.Type: ApplicationFiled: March 2, 2006Publication date: January 22, 2009Inventors: Laurence S. Harbige, Michael J. Leach, Paul Barraclough
-
Publication number: 20080207576Abstract: The invention discloses substituted sapogenins and their use in the treatment of cognitive disfunction and similar conditions.Type: ApplicationFiled: August 23, 2007Publication date: August 28, 2008Inventors: Paul Barraclough, Jim Hanson, Phil Gunning, Daryl Rees, Zongqin Xia, Yaer Hu
-
Publication number: 20080194684Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of ?-linolenic acid, dihomo-?-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-? levels in the patient to therapeutic levels.Type: ApplicationFiled: August 13, 2004Publication date: August 14, 2008Applicant: BTG International LimitedInventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief, Paul Barraclough
-
Publication number: 20080045591Abstract: Compounds of general formula I: wherein: R1 and R2 are, independently of each other, selected from hydrogen, optionally substituted C1-10alkyl, optionally substituted —CO—(C1-10alkyl), optionally substituted C3-10cycloalkyl, optionally substituted —CO—(C3-10cycloalkyl), optionally substituted C2-10alkenyl, optionally substituted —CO—(C2-10alkenyl), optionally substituted aryl, and optionally substituted —CO-aryl, or R1 and R2 together represent an optionally substituted saturated or unsaturated C1-10alkylidene group, or an optionally substituted saturated or unsaturated C3-10cycloalkylidene group, or R1 and R2 together with the carbon atom to which they are attached represent an optionally substituted saturated or unsaturated organic ring containing 3, 4, 5, 6, 7 or 8 ring carbon atoms and optionally 1, 2 or 3 ring heteroatoms selected from O, N and S; R3, which may be the same as, or different from, either of R1 and R2, is selected from optionally substituted C1-10alkyl, optionally substituted C3-10cycType: ApplicationFiled: July 5, 2007Publication date: February 21, 2008Inventors: Daryl Rees, Phillip Gunning, Antonia Orsi, Patrick Howson, Paul Barraclough, Noelle Callizot
-
Publication number: 20080020021Abstract: The invention discloses the use of 5-hydroxysapogenin derivatives in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed.Type: ApplicationFiled: August 20, 2007Publication date: January 24, 2008Applicant: PHYTOPHARM PLCInventors: Paul Barraclough, Jim Hanson, Phil Gunning, Daryl Rees, Zongqin Xia, Yaer Hu
-
Publication number: 20080021004Abstract: The invention discloses the use of sapogenin derivatives in the treatment of cognitive dysfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed.Type: ApplicationFiled: August 20, 2007Publication date: January 24, 2008Applicant: PHYTOPHARM PLCInventors: Paul Barraclough, Jim Hanson, Phil Gunning, Daryl Rees, Zongqin Xia, Yaer Hu